ClinicalTrials.gg
RecruitingNCT06083025CleaRingUpdated Oct 13, 2023

Influence of CleaRing Open-capsule Device on Refractive Predictability in Cataract Patients (Part 2)

An interventional study of CleaRing in Posterior Capsule Opacification, sponsored by Hanita Lenses. Recruiting at 1 site in Israel. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Hanita Lenses · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Apr 2023, registered Oct 2023).
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cataract by Hanita Lenses — 2 open to participants now, 2 under way, none of them phase 3. Cataract · Hanita Lenses.

Started
2023
with 3 others
No phase
8 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Cataract by Hanita Lenses, this one is one of 4 that started in 2023, is one of 8 with no phase, and was the 9th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

2 of the 10 studies in Cataract by Hanita Lenses are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cataract by Hanita Lenses, or all of them as a file.
02

Study summary

The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.

Read the detailed description

Cataract surgery has undergone significant improvement in terms of surgical technique, instrumentation and the quality of intraocular lenses (IOLs) over the past decades. Although the rate of posterior capsular opacification (PCO) has decreased, it is still the most common complication following uneventful cataract surgery, with the rate of laser capsulotomy ranging from 10% to 37%1-5 ND:YAG capsulotomy is a highly successful treatment, but it is not free of complications, such as increased intraocular pressure (IOP), pitting or dislocation of the IOL, cystoid macular edema, and retinal detachment. PCO also places an economic burden on the healthcare system. The importance of PCO prevention has increased in recent years, due to the expanding popularity of premium IOLs. Patients implanted with a premium IOL usually have high demands with regard to outcome, and PCO can also have an earlier effect on the performance of a premium IOL (i.e., multifocal IOLs).

Previous attempts to prevent PCO have included investigations of various IOL materials and designs, surgical techniques, and pharmacological materials. Unexpectedly lower PCO rates were recently noticed in eyes that were implanted with a special type of IOL, e.g., the Synchrony IOL (AMO, Santa Ana, CA, USA)8 and the FluidVision IOL (PowerVision, Belmont, CA, USA). It was hypothesized that the capsular bag stayed open due to the special design of these IOLs, and that this should reduce the PCO rate. Based upon this concept, a special open capsule ring was designed for intracapsular implantation in an attempt to maintain the capsular bag open and to reduce PCO rate. Safety and efficacy of the device was demonstrated through several animal studies. The tested devices were effective in reducing posterior capsule opacification and Soemmering's ring formation by 69% to 77% compared to control group. The Hanita CleaRing device is designed to be implanted in the capsular bag together with a standard posterior chamber IOL in a minimally invasive cataract surgery. The device is intended to reduce posterior capsular opacification leading to reduced Nd:YAG treatment rate. The raw material of the device is a hydrophilic co-polymer, considered to be biocompatible and practically inert to the eye tissue. The objective of this study is to evaluate the safety and the efficacy of CleaRing device in cataract patients.

03

Conditions studied

  • Posterior Capsule Opacification

Browse trials for

Keywords

  • Posterior capsule opacification
  • Cataract
  • Ring
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is between 50 and 80 years of age
  • Subject is designated for bilateral cataract surgery
  • Both eyes fulfil the following criteria:

    • Potentially able to achieve a good vision (by opinion of the investigator)
    • ACD is at least 2.5mm (from epithelium)
    • Corneal astigmatism is at most 2.0 dpt
    • Axial length is between 22.0 and 26.0 mm
    • Able to obtain pupil dilation of at least 6.0 mm
    • Average keratometry values between 42.0 and 46.0 D
  • Subject understands the study requirements and the treatment procedures and provides written before any study-specific tests or procedures are performed

Exclusion criteria

Exclusion Criteria:

  • Subject diagnosed with glaucoma of any type or having intraocular pressure above 24mmHg
  • Subject who has undergone previous intraocular surgery
  • Subject with corneal abnormality that would prevent stable and reliable refraction
  • Subject with weak or torn zonules
  • Subject with Pseudoexfoliation syndrome (PEX)
  • Subject with amblyopia
  • Subject with retinal disease that in the opinion of the principal investigator would prevent stable and reliable refraction or might be worsened due to implantation of the device
  • Subject is diagnosed with active anterior segment intraocular inflammation
  • Subject is obligated to previous participation in another study with any drug or device within the past 30 days
  • Subject is pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    CleaRing device for cataract patients

    All subjects who meet eligibility requirements will be asked to participate. Subjects will be considered enrolled into the study after: 1. A signed Informed Consent has been obtained. 2. The subject has met all of the inclusion and none of the exclusion criteria. 3. The ability of the subject to safely undergo cataract surgery under local anesthesia was confirmed by the investigator, according to standard procedure of the medical center.

    Device: CleaRing

Interventions

  • DeviceCleaRing

    The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.

06

What researchers measure

Primary outcomes

  1. The first primary objective of this study is to evaluate the influence of Clearing open-capsule device on refractive predictability in cataract patients.

    Refractive will be evaluated by Automated refraction

    Time frame: 1, 3 and 5 years

  2. The second primary objective of this study is to evaluate the influence of Clearing open-capsule device on refractive predictability in cataract patients.

    Refractive will be evaluated by subjective refraction

    Time frame: 1, 3 and 5 years

  3. The third primary objective of this study is to evaluate the influence of Clearing open-capsule device on refractive predictability in cataract patients.

    Refractive will be evaluated by visual acuity measurement.

    Time frame: 1, 3 and 5 years

Secondary outcomes

  1. Secondary objective of this study is to evaluate the influence of the device on PCO rate

    PCO will be evaluated by using Biomicroscopy (Slit Lamp)

    Time frame: 1, 3 and 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2025, 22 months after the start.

Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 22 months is above that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 13, 2023
StartActual
Apr 15, 2023
Primary completionEst.
Mar 1, 2025
CompletionEst.
Apr 1, 2025
Last update
Oct 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06083025
Lead sponsor
Hanita Lenses
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Apr 15, 2023
Primary completion
Mar 1, 2025 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Oct 13, 2023

Study contacts

Inbal Ratner
Contact
inbalr@wmc.gov.il
035028702 ext. +972
Guy Kleinmann, Prof.
principal investigator · Wolfson MC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion